Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APX 3330

Next Previous
X
Search
Drug Profile

APX 3330

Alternative Names: APX-3330; E-3330

Latest Information Update: 24 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals; Opus Genetics
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Neuroprotectants; Quinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; APEX1 protein inhibitors; DNA-apurinic apyrimidinic site lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Hepatitis B; Hepatitis C; Liver cirrhosis
  • Phase I Solid tumours
  • Preclinical Inflammatory bowel diseases; Pancreatic cancer
  • Discontinued Haematological malignancies; Liver disorders; Peripheral nervous system diseases

Most Recent Events

  • 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
  • 13 Aug 2024 Ocuphire Pharma files special protocol assessment (SPA) to US FDA for phase II/III trial for Diabetic retinopathy
  • 06 Jun 2024 Ocuphire plans a phase II/III ZETA-2 pivotal trial for Diabetic retinopathy in early 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top